ZDF
Sign inSign up

Vulnerabilities

Vulnerability · CVE-2026-28473

OpenClaw versions prior to 2026.2.2 contain an authorization bypass vulnerability where clients with operator.write scope can approve or deny exec approval requests by…

Published Mar 5, 2026 · catalog updated Jun 17, 2026 · the affected product

Check if you run it

No confirmed exploitation is on record for CVE-2026-28473. EPSS is 0.52%. Act only if a listed version of the affected product is installed.

Gaps on this record

  • No plain product name is stored. The page cannot tell you which product to check.
  • No version range is stored. A customer cannot check an installed version against this record.
  • No vendor fix or required action is stored. Compare the linked advisory before you change production.
Severity
High7.2
Known exploitation
Not in CISA/VulnCheck KEV
EPSS
0.52%
Remediation
Advisory link
Affected products
cpe openclaw/openclaw

OpenClaw versions prior to 2026.2.2 contain an authorization bypass vulnerability where clients with operator.write scope can approve or deny exec approval requests by sending the /approve chat command. The /approve command path invokes exec.approval.resolve through an internal privileged gateway client, bypassing the operator.approvals permission check that protects direct RPC calls.

Are you affected?

Enter the version you run. The result uses only the ranges stored on this record.

The check returns affected, not affected, or incomplete. It does not guess a version that is missing from the record.

  • cpe openclaw/openclawversion unspecified

How to fix CVE-2026-28473

What to do

Three questions, each answered from this record only. Confirm the vendor advisory before you patch.

Should you patch?

No confirmed exploitation is on record for CVE-2026-28473. EPSS is 0.52%. Act only if a listed version of the affected product is installed.

Which versions are affected?

Affected version ranges are not on this record. Compare the installed version with the linked vendor advisory before you change production.

What should an analyst verify?

CWE-863: Incorrect Authorization. EPSS 0.52%. There is no CISA KEV listing. No Exploit-DB or Metasploit reference is linked. Use the source links for the original advisory.

Code

The project this record applies to. Exploit listings stay in References.

Timeline

Detection, updates, and resolution for this record.

  1. Mar 5, 2026 · NIST NVD

    Detected

    OpenClaw versions prior to 2026.2.2 contain an authorization bypass vulnerability where clients with operator.write scope can approve or deny exec approval requests by sending the /approve chat command. The /approve command path invokes exec.approval.resolve through an internal privileged gateway client, bypassing the operator.approvals permission check that protects direct RPC calls.

  2. Jun 17, 2026 · NIST NVD

    Updated

    OpenClaw versions prior to 2026.2.2 contain an authorization bypass vulnerability where clients with operator.write scope can approve or deny exec approval requests by sending the /approve chat command. The /approve command path invokes exec.approval.resolve through an internal privileged gateway client, bypassing the operator.approvals permission check that protects direct RPC calls.

Sources

  • CVE.orgVulnerability recordCVE-2026-28473

    Official CVE identifier

    cve.org
  • FIRST EPSSExploitation probabilityCVE-2026-28473

    30-day exploitation probability 0.5%

    first.org
  • NIST NVDVulnerability recordCVE-2026-28473

    OpenClaw versions prior to 2026.2.2 contain an authorization bypass vulnerability where clients with operator.write scope can approve or deny exec approval requests by sending the /approve chat command. The /approve command path invokes exec.approval.resolve through an internal p

    nvd.nist.gov

References

Freshness

Last verified in this catalog Oct 18, 2026. Significant claims (KEV, EPSS, CVSS, affected ranges) come from the source rows above — open the original publisher for the authoritative advisory.